On February 27, 2014 Immune Design announced treatment of the first patient in a Phase 1 clinical trial of ID-G305 (Press release Immune Design, FEB 27, 2014, View Source [SID:1234500179]).
The Phase 1 open label, dose-escalation trial is designed to evaluate the safety, tolerability and immunogenicity of ID-G305 in patients with unresectable, relapsed, or metastatic cancer expressing the NY-ESO-1 antigen, including melanoma, sarcoma, lung, ovarian or breast cancer. The trial is being conducted in up to 18 patients at several clinical centers in the United States.